Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of ustekinumab in adolescents
Jonathan I. Silverberg, Mark Lebwohl, Roselyn Kellen
Pediatric Health Medicine and Therapeutics (2016) Vol. Volume 7, pp. 109-120
Open Access | Times Cited: 19

Showing 19 citing articles:

Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients
Matteo Megna, Elisa Camela, Teresa Battista, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 1, pp. 25-41
Closed Access | Times Cited: 42
Current and emerging biologics for the treatment of juvenile idiopathic arthritis
Rolando Cimaz, Gabriella Maioli, Giulia Calabrese
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 7, pp. 725-740
Open Access | Times Cited: 30
Current and emerging prospects in the psoriatic treatment
Rutuja Vilas Nikam, M Gowtham, Pratiksha Sanjay More, et al.
International Immunopharmacology (2023) Vol. 120, pp. 110331-110331
Closed Access | Times Cited: 10
Hair and skin predict cardiomyopathies: Carvajal and erythrokeratodermia cardiomyopathy syndromes
Qisi Sun, Lara Wine Lee, E. Kevin Hall, et al.
Pediatric Dermatology (2020) Vol. 38, Iss. 1, pp. 31-38
Closed Access | Times Cited: 17
Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis—Insights From Other Diseases
Romy E. Hoeppli, Anne M. Pesenacker
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 15
Biological therapy in genital psoriasis in women
Martina Burlando, Astrid Herzum, Luca Carmisciano, et al.
Dermatologic Therapy (2019) Vol. 33, Iss. 1
Open Access | Times Cited: 15
FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review
Nida Aslam, Hajra Saleem, Salikh Murtazaliev, et al.
Cureus (2020)
Open Access | Times Cited: 13
The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis
Martina Burlando, Roberto Russo, Andrea Clapasson, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3140-3140
Open Access | Times Cited: 12
Recent progress in the treatment of non-systemic juvenile idiopathic arthritis
J. M. Bridges, Elizabeth Mellins, Randy Q. Cron
Faculty Reviews (2021) Vol. 10
Open Access | Times Cited: 11
Administration Details of Genetically Engineered Biologic Drug (Ustekinumab) in Children with Psoriasis and Comorbid Metabolic Syndrome or in Case of Previous Biological Therapy Failure: Case Studies
Roman A. Ivanov, Nikolay N. Murashkin
Вопросы современной педиатрии (2022) Vol. 21, Iss. 5, pp. 419-429
Open Access | Times Cited: 4
Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management
Katherine A. Kelly, Adaora Ewulu, Veronica K. Emmerich, et al.
Biomedicines (2021) Vol. 9, Iss. 8, pp. 958-958
Open Access | Times Cited: 5
Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia
Ahmad Alamer, Wejdan Alyazidi, Saad A. Aldosari, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Pediatric Psoriasis: Biologics and Oral Small Molecule Inhibitors in Modern Therapy
Alexandra Firek, Leslie Castelo-Soccio
JAAD reviews. (2024) Vol. 3, pp. 51-56
Open Access
Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions
Rocío Sedaño, Ahmed Almradi, Christopher Ma, et al.
Current Treatment Options in Gastroenterology (2020) Vol. 18, Iss. 3, pp. 442-461
Closed Access | Times Cited: 3
Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients
Florence Libon, Eve Lebas, Virginie de Schaetzen, et al.
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 9, pp. 947-955
Closed Access | Times Cited: 3
Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children
Roman A. Ivanov
Medical alphabet (2022), Iss. 8, pp. 80-85
Closed Access | Times Cited: 2
Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis
Jennifer Clay Cather, Chaney T. Young, Melody S. Young, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 8, pp. 983-990
Closed Access | Times Cited: 2
Interleukin 12/23 Inhibitors
Hee J. Kim, Mark Lebwohl
Elsevier eBooks (2020), pp. 302-311.e2
Closed Access | Times Cited: 1
Ustekinumab in Pediatric Dermatology: An Updated Review
A.S. Chehad, Nada Boutrid, Hakim Rahmoune
Journal of Exploratory Research in Pharmacology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 1
Page 1

Scroll to top